"The Report
Iguratimod/T-614 (Rheumatoid Arthritis) - Forecast and Market
Analysis to 2023 provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
Description
Iguratimod/T-614 (Rheumatoid
Arthritis) - Forecast and Market Analysis to 2023
Summary
Rheumatoid arthritis (RA) is a
chronic autoimmune disease which causes inflammation and deformity of
the joints . It affects over seven million individuals in the 10MM
covered in this report (US, France, Germany, Italy, Spain, UK, Japan,
Australia, China, and India) and the prevalence is expected to grow
to just over 8.5 million individuals by 2023. The anti-TNFs have been
effective in treating the signs and symptoms of RA and inhibiting
progression to erosive bone disease. However, the landscape is
quickly changing with the introduction of biosimilars, novel
biologics, and a class of oral therapies known as JAK inhibitors, all
of which will change the market dynamics between 2013 and 2023. With
the anti-TNFs as extremely effective therapies for RA, the market is
extremely competitive for new entrants and will undergo further
pressure as biosimilars are approved and launch.
Iguratimod (T-614) was
approved in Japan in June 2012, and was subsequently launched the
following September for the treatment of adults with active RA as an
add-on to MTX in patients who are not adequately controlled by
monotherapy (Eisai, press release, September 11, 2012). It was also
approved in China in 2012.
View Full Report at
http://www.marketresearchreports.biz/analysis/247149
Scope
- Overview of Rheumatoid
Arthritis, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
competitive landscape.
- Detailed information on
Iguratimod/T-614 including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for
Iguratimod/T-614 for the top 2 countries from 2013 to 2023.
- Sales information covered
for Japan and China.
Reasons
to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return.
- Stay ahead of the
competition by understanding the changing competitive landscape for
Rheumatoid Arthritis.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential.
- Make more informed business
decisions from insightful and in-depth analysis of Iguratimod/T-614
performance.
- Obtain sales forecast for
Iguratimod/T-614 from 2013-2023 in top 2 countries (Japan and China).
Download
Detail Report With Complete TOC at
Table
of Content
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports
13
3 Disease Overview 14
3.1 Etiology and
Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 14
3.2 Symptoms 19
3.3 Prognosis 20
3.4 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis and Treatment
Overview 21
4.1.1 Diagnosis 21
4.1.2 Treatment Guidelines 23
4.1.3 Leading Prescribed Drugs
for the Treatment of RA 32
4.1.4 Clinical Practice 34
5 Competitive Assessment 39
5.1 Overview 39
6 Iguratimod/T-614 41
6.1 Overview 41
6.2 Efficacy 42
6.3 Safety 43
6.4 SWOT Analysis 43
6.5 Forecast 44
7 Appendix 45
Browse
Latest News at http://www.marketresearchreports.biz/articles
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment